Jasper Therapeutics IncNASDAQ:JSPR
- LAST PRICE0.7500
- TODAY'S CHANGE (%)-0.0210 (-2.7237%)
- Bid / Lots0.7400/ 5
- Ask / Lots0.7500/ 3
- Open / Previous Close0.7579 / 0.7710
- Day Range
- 52 Week Range
- Volume53,337
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | JSPR |
|---|---|---|
| 09:32 ET | 1997 | 0.795 |
| 09:36 ET | 5707 | 0.76 |
| 09:38 ET | 300 | 0.76 |
| 09:45 ET | 200 | 0.76 |
| 09:48 ET | 1100 | 0.785 |
| 09:56 ET | 1300 | 0.76 |
| 09:57 ET | 2802 | 0.76 |
| 09:59 ET | 1973 | 0.7725 |
| 10:01 ET | 489 | 0.76 |
| 10:15 ET | 536 | 0.7582 |
| 10:19 ET | 200 | 0.76 |
| 10:28 ET | 1628 | 0.75 |
| 10:30 ET | 27598 | 0.75 |
Today
Sep 15, 2023
Jasper Therapeutics to Present at the Cantor Fitzgerald 2023 Global Healthcare Conference, from 8:00AM ET on Friday Sep 15, 2023 by Dow Jones
8:00AM ET on Friday Sep 15, 2023 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Jasper Therapeutics Inc | 85.4M | -0.8x | --- |
NDT Pharmaceuticals Inc | 81.6M | 0.0x | --- |
China Health Industries Holdings Inc | 72.1M | 102.5x | --- |
Eyenovia Inc | 70.3M | -2.4x | --- |
Bright Green Corp | 69.1M | -5.0x | --- |
Spectral Medical Inc | 76.6M | -14.1x | --- |
Company Information
Jasper Therapeutics, Inc. is a biotechnology company. The Company is engaged in the development and commercialization of therapeutic agents for diseases, such as Chronic Spontaneous Urticaria (CSU), Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS) and conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The Company's lead product candidate, briquilimab, is in clinical development as a therapeutic antibody that targets mast and stem cells in various diseases and as a conditioning agent to clear hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. The Company is also developing engineered hematopoietic stem cell product candidates reprogrammed using mRNA delivery (mRNA stem cell platform) and gene editing.
Contact Information
- Headquarters
- 2200 Bridge Pkwy Suite #102REDWOOD CITY, CA, United States 94065
- Phone
- 650-549-1400
- Fax
- 302-636-5454
Executives
- Chairman of the Board
- William Lis
- President, Chief Executive Officer, Director
- Ronald Martell
- Chief Financial Officer, Chief Operating Officer, Corporate Secretary
- Jeetinder Mahal
- Director
- Scott Brun
- Director
- Judith Shizuru
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $85.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 110.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.98 |
EPS | $-0.99 |
Book Value | $0.95 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
